Table 2. Occurrence of invasive cancers at specific sites subsequent to breast carcinoma in situ.

Site	Observed	Expected	SIR	95% CI
Head and neck	19	25.03	0.76	0.46–1.19
Oesophagus	22	22.85	0.97	0.60–1.46
Stomach	26	32.82	0.79	0.52–1.16
Colorectal	130	147.93	0.88	0.73–1.04
Pancreas	22	37.20	0.59	0.37–0.90
Lung	101	133.92	0.75	0.61–0.92
Malignant melanoma	14	21.80	0.64	0.35–1.08
Breast	512	261.44	1.96	1.79–2.14
Cervix uteri	12	20.39	0.59	0.30–1.03
Corpus uteri	74	52.14	1.42	1.11–1.78
Ovary	49	59.81	0.82	0.61–1.08
Kidney	16	16.02	1.00	0.57–1.62
Bladder	22	30.13	0.73	0.46–1.11
Non-Hodgkin's lymphoma	24	35.56	0.67	0.43–1.00
Multiple myeloma	11	16.00	0.69	0.34–1.23
Leukaemia	20	24.93	0.80	0.49–1.24
Othersa	72	138.28	0.52	0.41–0.66
All sitesa	1146	1076.25	1.06	1.00–1.13

CI=confidence interval; SIR=standardised incidence ratio.

^aExcluding non-melanoma skin cancers.